https://www.selleckchem.com/Bcl-2.html
To conduct a comprehensive pharmacoeconomic evaluation of lurasidone for the treatment of patients with schizophrenia under Russian healthcare system conditions and inclusion in EDL (Essential Drugs List) and Medication List for the Certain Categories of Citizens. A retrospective study of lurasidone in the treatment of patients with schizophrenia was performed. Methods of pharmacoeconomic analysis were cost analysis, budget impact analysis and cost-effectiveness analysis. Use of lurasidone for the treatment of patients with schizophrenia requires
Curtir
Comentario
Compartilhar
